Endpoints News

Why is it so hard for retailers to do primary care? That was a question I had on my mind while chatting with execs at HLTH last month. Read how Kroger's Colleen Lindholz, Amazon Pharmacy's John Love and Walgreens' Mary Langowski weighed in in today's Endpoints News Health Tech newsletter. Also inside: - Ngai Yeung has the scoop on layoffs at Maven Clinic - Shelby Livingston spoke with Ferrum Health, Inc.'s Pelu Tran about why AI adoption for clinical purposes within hospitals has been slow - Updates from hims & hers' earnings call + CMS payments for digital therapeutics Check it out! https://lnkd.in/gf9i-TVD

It's Election day in the US. Here's what might be at stake for the #pharma industry with a new administration, what would you add? https://lnkd.in/eUC-PVPw

Why is it so hard for retailers to do primary care? That was a question I had on my mind while chatting with execs at HLTH last month. Read how Kroger's Colleen Lindholz, Amazon Pharmacy's John Love and Walgreens' Mary Langowski weighed in in today's Endpoints News Health Tech newsletter. Also inside: - Ngai Yeung has the scoop on layoffs at Maven Clinic - Shelby Livingston spoke with Ferrum Health, Inc.'s Pelu Tran about why AI adoption for clinical purposes within hospitals has been slow - Updates from hims & hers' earnings call + CMS payments for digital therapeutics Check it out! https://lnkd.in/gf9i-TVD

AstraZeneca has entered the obesity race - and it wants to win. The British pharma giant came with three new assets to #ObesityWeek2024 in the hopes to “move beyond short-term weight loss”. Full story by Kyle LaHucik: https://lnkd.in/eBNK2i3A

Can GLP-1 drugs also help MASH patients? Eli Lilly and Company reported in June that its weight loss drug tirzepatide might be an effective treatment, and last week Novo Nordisk released a study showing that its weight loss drug semaglutide also improved MASH in patients. Max Bayer reports: https://lnkd.in/e-JmS3kX

More on the Novo Holdings - Catalent Pharma Solutions deal: The European Comission has set December 6 as its deadline to decide if the deal passes antitrust review. The US Federal Trade Comission is set to decide by the end of the year. Read the full story: https://lnkd.in/eeHap7Dq

Friday scoop by Ngai Yeung: Maven Clinic cuts 10% of its workforce after raising a $125M Series F round. Read more (and sign up to HealthTech): https://lnkd.in/eVSUs-vX

In this week's Peer Review https://lnkd.in/eSMFvHDJ: - Biogen gets a new CFO and a new CMO; - MacroGenics is set to replace CEO Scott Koenig; - Abdul Mullick will take over as president of Kyowa Kirin; - Alkeus Pharmaceuticals enlists David Arkowitz as CFO; - Robin Kleiman joins Myrobalan Therapeutics as CSO

Kyle LaHucik will be on the ground covering #ObesityWeek in San Antonio. Will you be attending? Read his interview with The Obesity Society here: https://lnkd.in/eMqgfeN6

It's going to be incredibly hard to put the compounding pharmacy genie back in the bottle. That's what's on Shelby Livingston's mind coming off of Eli Lilly and Company's earnings yesterday. You can read all about it in the latest edition of the Endpoints News Health Tech newsletter. Also inside today's newsletter: - I chatted with Mary Langowski about her strategy for Walgreens' US healthcare business - Ngai Yeung spoke with Define Ventures Lynne Chou O'Keefe about evolving AI strategies - We break down earnings from Talkspace, Teladoc Health, Humana + Cigna Healthcare Check it out: https://lnkd.in/eAyuAnxB